



Samrat Pharmachem Limited

Manufacturers & Exporters of Pharmaceutical Chemicals

Regd. Office & Factory

Plot No. A2/3445, GIDC, Phase 4,
Opp. PCI, Ankleshwar – 393 002,
Gujarat, India
Tel : +91-7045456789 / 7046456789
Web: www.samratpharmachem.com

CIN: L24230GJ1992PLC017820

Corporate Office

701/702, Business Square,
M. A. Road, Andheri (West),
Mumbai – 400 058, India.
Tel : (91-22) 26701050/1/2
Email: contact@samratpharmachem.in

January 4, 2023

To,
**Department of Corporate Services,
BSE Limited**
P J Towers,
Dalal Street,
Mumbai - 400 001.

Ref: Scrip Code: 530125

Dear Sir/Madam,

Sub: Intimation under Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Please find enclosed the intimation letter dated January 2, 2023, received from our Registrar and Share Transfer Agent, Link Intime India Private Limited, providing information regarding issue of duplicate share certificates to the shareholder(s) of the Company.

The information is being submitted pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Kindly take the same on your records.

Thanking you,

Yours faithfully,
For Samrat Pharmachem Limited

Nishant Kankaria
Company Secretary and Compliance Officer

Samrat Pharmachem Limited

From: Aarya Patankar <aarya.patankar@linkintime.co.in>
Sent: 02 January 2023 17:56
To: 'Samrat Pharmachem Limited'
Cc: 'Nikita Jirepatil'; 'Aqueel Mulla'
Subject: RE: Approval Date for Duplicate_ 0011423
Attachments: TN22.pdf

Dear Sir,

Please find the attached register for Duplicate for the below mentioned folio in the trail mail.

Thanks & Regards,

Aarya Patankar

Associate - Client relation Link Intime India Pvt. Ltd
P: +91 22 49186000 (Extn: 2322) M: +91 9082237936 F: +91 22 49186060
E: aarya.patankar@linkintime.co.in W: www.linkintime.co.in

Our Product Offerings

-----Original Message-----

From: Samrat Pharmachem Limited [mailto:contact@samratpharmachem.in]
Sent: Thursday, December 29, 2022 13:22
To: 'Aarya Patankar' <aarya.patankar@linkintime.co.in>
Cc: 'Nikita Jirepatil' <nikita.jirepatil@linkintime.co.in>; 'Aqueel Mulla' <aqueelmulla@gmail.com>;
contact@samratpharmachem.in
Subject: RE: Approval Date for Duplicate_ 0011423

Approval Date: 02-01-2023

Best Regards,

Sheetal
Samrat Pharmachem Limited

-----Original Message-----

From: Aarya Patankar [mailto:aarya.patankar@linkintime.co.in]
Sent: 27 December 2022 17:38
To: contact <contact@samratpharmachem.in>; sheetal <sheetal@samratpharmachem.com>
Cc: Nikita Jirepatil <nikita.jirepatil@linkintime.co.in>
Subject: Approval Date for Duplicate_ 0011423

Dear Sir,

Please note that we have received documents for Duplicate.
Kindly arrange to provide approval date for the same for below mentioned folio:

Folio no.: 0011423

Thanks & Regards,
Aarya Patankar
Link Intime India Pvt. Ltd.
DISCLAIMER:

This email (which includes any attachments or links to other websites) is intended solely for the named addressee. It is confidential and may contain legally privileged information. Delivery to any person other than the named addressee does not waive privilege or confidentiality. If you have received this email in error, let us know by reply email, delete it from your system and destroy any copies. This email is also subject to copyright. You must not reproduce or distribute it without our consent. We believe that information contained in this email is correct but we give no warranty as to its accuracy or completeness. It is provided as general information only and does not take into account your particular circumstances. It does not purport to be investment advice and you must not act in reliance on it. To the extent permitted by law, we disclaim all liability (including liability for negligence) for direct or indirect loss or damage suffered by any recipient acting in reliance on this email. This email may contain information or links to websites prepared by people who are not our employees or representatives. Such information will be identified as the product of an independent third party. It is provided for your interest and convenience only. We have not independently verified (and to the extent permitted by law disclaim all liability for) its accuracy or completeness and it does not constitute our recommendation or opinion. Emails may be interfered with, may contain computer viruses or other defects and may not be successfully replicated on other systems. It is the responsibility of the recipient to verify the integrity and authenticity of this email and to ensure that any attachments are scanned for viruses.

DISCLAIMER:

This email (which includes any attachments or links to other websites) is intended solely for the named addressee. It is confidential and may contain legally privileged information. Delivery to any person other than the named addressee does not waive privilege or confidentiality. If you have received this email in error, let us know by reply email, delete it from your system and destroy any copies. This email is also subject to copyright. You must not reproduce or distribute it without our consent. We believe that information contained in this email is correct but we give no warranty as to its accuracy or completeness. It is provided as general information only and does not take into account your particular circumstances. It does not purport to be investment advice and you must not act in reliance on it. To the extent permitted by law, we disclaim all liability (including liability for negligence) for direct or indirect loss or damage suffered by any recipient acting in reliance on this email. This email may contain information or links to websites prepared by people who are not our employees or representatives. Such information will be identified as the product of an independent third party. It is provided for your interest and convenience only. We have not independently verified (and to the extent permitted by law disclaim all liability for) its accuracy or completeness and it does not constitute our recommendation or opinion. Emails may be interfered with, may contain computer viruses or other defects and may not be successfully replicated on other systems. It is the responsibility of the recipient to verify the integrity and authenticity of this email and to ensure that any attachments are scanned for viruses.

REGISTER OF NEW SHARE CERTIFICATES ISSUED ON DUPLICATION

FROM: TN22 TO: TN22

SR NO.	FOLIO NO. SHAREHOLDER'S NAME	FROM	TO	FROM	TO	SHARES	PAID	STUS	Deno	Cert Type	MICR From	MICR To
TN22 02/01/2023	0011423 HASUBHAI MANILAL SONI											
		13461	13462	1346001	1346200	200 OLD	10.00	DUP	200			
						----- 200						
		30972	30972	1346001	1346200	200 NEW	10.00		200			
						----- 200						

Samrat Pharmachem Limited

REGISTER OF NEW SHARE CERTIFICATES ISSUED ON DUPLICATION

FROM: TN22 TO: TN22

***** BATCH CONTROLS*****

1. TOTAL NO.OF REQUESTS	:	1
2. TOTAL NO.OF OLD CERTIFICATES	:	2
3. TOTAL NO.OF NEW CERTIFICATES	:	2
4. TOTAL NO.OF PAGES	:	2

***** CERTIFICATE (S)CONTROLS*****

5. TOTAL NO.OF DUPLICATED CERTIFICATE	:	1
6. TOTAL NO.OF DUPLICATED SHARES	:	200
7. TOTAL NO.OFSUB DIVIDED CERTIFICATE	:	0
8. TOTAL NO.OFSUB DIVIDED SHARES	:	0
9. TOTAL NO.OF CONSOLIDATED CERTIFICATE	:	0
10.TOTAL NO.OF CONSOLIDATED SHARES	:	0